[Prevention and treatment with cefoperazone of postoperative suppurative complications in heart surgery].
Clinical trials of cefoperazone (cefobid, Pfizer, USA) were carried out in 49 patients with cardiovascular diseases who had undergone surgical operations. The pathogens of infectious complications were investigated bacteriologically. Good results of the treatment were observed in 43 patients. Allergic reaction developed in 1 patient. Cefoperazone was shown advantageous in treatment of pulmonary complications in the operated patients. It was found possible to use cefoperazone in combination with aminoglycosides. Cefoperazone was found to be one of the drugs of choice in the treatment of aerobic and anaerobic bacteriemia, as well as sepsis after surgical operations on the heart and great vessels. The results on the use of cefoperazone for short-term "perioperative" prophylaxis in cardiosurgery (in accordance with the WHO instructions) are also presented.
Nemchenko
V I
VI
D001021:Aortic Valve / Q000601:surgery*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002438:Cefoperazone / Q000008:administration & dosage / Q000627:therapeutic use*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003327:Coronary Disease / Q000601:surgery*; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008943:Mitral Valve / Q000601:surgery*; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D014261:Tricuspid Valve / Q000601:surgery*
D002438:Cefoperazone
Profilaktika i terapiia cefoperazonom posleoperatsionnykh gnoĭnykh oslozhneniĭ v kardiokhirurgii.